XWPharma is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for central nervous system (CNS) disorders. The company employs a proprietary drug discovery methodology that emphasizes mechanisms of action validated through clinical studies and medical practice. Their investigational therapies, such as valilxoybate and XW10508, are designed to leverage time-regulated neurobiology, aiming to provide effective treatment options for conditions like narcolepsy, non-motor symptoms of Parkinson's disease, major depressive disorder, and chronic pain. These therapies are characterized as new chemical entities (NCEs) with unique features and intellectual property, targeting high-value commercial markets with favorable reimbursement prospects.

Valilxoybate is a GABA B agonist currently in development for treating sleep disorders associated with narcolepsy and Parkinson's disease, while XW10508 is a glutamatergic NMDA antagonist and AMPA activator aimed at providing fast-acting relief for treatment-resistant depression and chronic pain. Both compounds are positioned to address significant unmet medical needs, as existing treatments often fall short in efficacy or have limitations. XWPharma's strategic approach includes efficient development pathways to de-risk clinical programs early, ensuring a focus on therapies that can successfully navigate the complexities of clinical testing and commercialization.

United States

We are a global biotech with a pipeline of internally discovered novel small molecule drug candidates focused on neurological and neuropsychiatric disorders.

XWPharma

Company Details